Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYNB1891 + atezolizumab
- Development stage
- Unknown
- Lead developer
- Synlogic
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
SYNB1891 + atezolizumab is a combination therapy investigated for advanced/metastatic cancers, consisting of SYNB1891, a live, engineered strain of *Escherichia coli* Nissle 1917, and atezolizumab, a monoclonal antibody targeting PD-L1. SYNB1891 is designed to produce cyclic dinucleotides in hypoxic tumor environments, activating the STimulator of INterferon Genes (STING) pathway in phagocytic antigen-presenting cells, thereby stimulating innate immune responses and type I interferon signaling. Atezolizumab acts by inhibiting the PD-L1 pathway, counteracting tumor-mediated immune suppression and facilitating T-cell activity. Together, these agents are intended to synergistically enhance antitumor immune activity via innate and adaptive mechanisms. The combination was evaluated in a phase I trial for safety, tolerability, pharmacodynamics, and preliminary efficacy in patients with advanced/metastatic cancers[1][2][3][4].
- Other names
- SYNB1891SYNB-1891SYNB 1891Tecentriq
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on SYNB1891 + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYNB1891 + atezolizumab.